Meningococcal infection
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infections with bacteria of the species neisseria meningitidis.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Meningococcal infection
- Therapeutic area
- Infectious Disease
- meningococcal infection
- Neisseria meningitidis infection
- infections, Neisseria meningitidis
- meningococcal disease
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0005373
- Parent condition
- MONDO:0005113
Related records
Broader conditions (6)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
Narrower conditions (2)
- Meningococcal meningitis
- Meningococcemia
Trials (228)
- 36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds
- A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger
- A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
- A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
- A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
- A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
- A Sourcing Study to Collect Human Blood Samples From Healthy Adults
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India
- A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
- A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants
- A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
- A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
- A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
- A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Drugs in development (12)
- Azithromycin Phase 2
- Diphtheria toxoid Phase 3
- Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Phase 3
- Hepatitis B virus hbsag surface protein antigen Phase 3
- Measles virus vaccine live Phase 3
- Meningococcal polysaccharide vaccine group A Phase 3
- Meningococcal polysaccharide vaccine group C Phase 3
- Mumps virus vaccine live Phase 3
- Poliovirus vaccine inactivated Phase 3
- Rubella virus vaccine live Phase 3
- Sodium chloride Phase 2
- Tetanus toxoid Phase 3
Other linked drugs (6)
- Neisseria meningitidis adhesin A
- Neisseria meningitidis factor H binding protein
- Neisseria meningitidis neisserial heparin binding antigen
- Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae CRM197
- Neisseria meningitidis outer membrane vesicles
- Neisseria meningitidis polysaccharide conjugated to tetanus toxoid